3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
8
Carcinoma, Non-Small-Cell Lung
4
Neoplasm Metastasis
3
Melanoma
3
Colorectal Neoplasms
3
Stomach Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Neoplasms, Glandular and Epithelial
2
Neoplasms by Histologic Type
2
Liver Neoplasms
2
Kidney Neoplasms
2
Head and Neck Neoplasms
2
Glioblastoma
2
Central Nervous System Neoplasms
2
Carcinoma, Renal Cell
2
Brain Neoplasms
2
Adenocarcinoma
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Interventions
trifluridine tipiracil drug combination
1
rubitecan
1
repotrectinib
1
pevonedistat
1
pembrolizumab
1
ozanimod
1
linifanib
1
ledipasvir, sofosbuvir drug combination
1
fisogatinib
1
ficlatuzumab
1
durvalumab
1
avelumab
1
atezolizumab
1
Trabectedin
1
Sorafenib
1
Ramucirumab
1
Irinotecan
1
Immunotherapy
1
Electroporation
1
Dexamethasone
1
Bevacizumab
1
Azacitidine
1
Axitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Liver Diseases
×
Immunotherapy
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled